



We Report.
You Decide.

Sign Up Now
Get e-mail al
when news t

HOME U.S. WORLD VIDEO POLITICS OPINION BUSINESS MYNEWS HEALTH SPORTS SCITECH WEATHER ENTERTAINMENT
RADIO MOBILE FOX & Friends Studio B Your World Big Story Special Report FOX Report O'Reilly Factor
Hannity & Colmes On the Record FNC iMag FOX Fan

Important Safety Information

why Rozerem's different

subscribe to Newzzzz

ROZEREM™ is a trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc. LUVOX® (fluvoxamine) is a registered trademark of Soluqu Pharmaceuticals, Inc. ©2007 Takeda Pharmaceuticals North America, Inc. RAM-01235



Click here for a free 7-day trial of Rozerem

because your dreams miss you.



Health

FOXNEWS.COM HOME > HEALTH

HEALTH HOME

THINGS TO KNOW

LONGEVITY

HEART

PREGNANCY & PARENTING

HEALTH VIDEO

HEALTH CENTERS

- AGING
- ALLERGY / COLD & FLU
- ALTERNATIVE MEDICINE
- BEAUTY & SKIN
- CANCER
- DIABETES
- HEALTH TECH
- HEART DISEASE
- NEUROLOGY
- NUTRITION AND FITNESS
- PREGNANCY & PARENTING
- SEXUAL HEALTH
- SPORTS MEDICINE / ORTHOPEDICS

SPECIAL FEATURES

- ARTHRITIS
- HEADACHES & MIGRAINES

Senator Grassley's December 2007 Letter To FDA Questions Agency's Approval Of Ketek

Blog Name: Drug Injury Watch

Wednesday, January 02, 2008

Sanofi-Aventis Antibiotic Has Been Subject Of Controversy Since Reports of Liver Damage Surfaced In Early 2006

(Posted by Tom Lamb at DrugInjuryWatch.com)

The [safety concerns about Ketek \(telithromycin\) began in early 2006](#) after Health Canada and the European Union's European Medicines Agency (EMA) issued alerts based on the online "early" release of an article about Ketek that would later be published in the March 21, 2006 edition of the *Annals of Internal Medicine*. This article reported three cases in a North Carolina hospital where there was liver failure associated with Ketek use.

In [May 2006 Senator Charles Grassley \(R-Ill.\) as well as Congressmen Edward Markey \(D-Mass.\) and Henry Waxman \(D-Calif.\) asked the FDA for some explanation](#) about the agency's decision to approve the antibiotic Ketek in 2004. This scrutiny from Capitol Hill followed in the wake of a May 1, 2006 investigative piece in *The Wall Street Journal* about how the FDA approved Ketek despite knowing about some problems with a key study -- known as trial 3014 -- which was submitted to the FDA by Ketek's manufacturer, Sanofi-Aventis (SNY).

Finally, in [October 2007 the FDA posted on its web site a copy of an 11-page "Warning Letter" to Sanofi-Aventis](#) about problems with Ketek Study 3014.

Most recently, on [December 19, 2007 Senator Grassley, ranking member of the U.S. Senate Committee on Finance, sent a 22-page letter to FDA commissioner Andrew C. von Eschenbach, M.D.](#), regarding the Committee's ongoing investigation of Ketek.

In his letter Grassley reports what has been learned over the past 16 months, during which time the Committee's staff reviewed documents and information obtained from the Department of Health and Human Services (HHS), the FDA, FDA advisory committee members, and the drug company Sanofi-Aventis. The primary focus of Grassley's letter is the FDA's review of Sanofi-Aventis' Study 3014, and the FDA's unprecedented reliance on adverse-events data collected in foreign countries for evidence of Ketek's safety when approving this antibiotic for sale in the U.S.

Also in his December 19 letter to the FDA Commissioner Grassley presents the Committee's findings as regards some of the inspections and investigations conducted by FDA's Division of Scientific Investigations (DSI) and Office of Criminal Investigations (OCI) concerning alleged

■ THINGS YOU SHOULD KNOW

PET HEALTH

MENTAL HEALTH

NEWS ARCHIVE

HOT TOPICS

■ FOX NEWS ELECTION COVERAGE

■ CELEBRITY GOSSIP

SECTION MAP

SEE MORE

Send news tip to FOXNews.com

SUBMIT

improprieties and misconduct associated with Study 3014.

As regards the FDA's approval of Ketek on April 1, 2004, from the first few pages of this December 2007 letter from Senator Grassley we learn the following:

Current and former FDA employees alleged that FDA relied solely on foreign postmarketing adverse event reports as evidence of Ketek's safety for marketing when the Agency could no longer rely on the large safety study, Study 3014. These employees questioned whether or not the use of such data as the primary basis for the Agency's safety assessment of Ketek met the standards for approval of the drug....

FDA appears to have relied primarily on foreign post-marketing safety data to assess the safety of Ketek as a new antibiotic for marketing. Based on interviews with current and former FDA staff, heavy reliance on foreign post-marketing safety data in this context is unprecedented. A week before Ketek was approved, FDA's Division of Scientific Investigations concluded that the data from a large clinical trial were unreliable. The study was conducted to evaluate specific adverse events associated with Ketek. In place of the large clinical trial, the FDA based its assessment of the safety of Ketek on foreign post-marketing adverse event reports, despite inherent limitations with that data, including underreporting and reporting bias. When asked by Committee Staff, FDA managers and reviewers could not identify any other case where FDA relied on foreign postmarketing data as the primary basis of its safety assessment for the approval of a new antibiotic.

As the stated purpose of this December 19 letter to Dr. von Eschenbach was not only to report the Committee's findings but, also, to "request your comments and responses regarding these findings and some of the other allegations and concerns that have been brought to the Committee's attention", we will likely be reporting more about Ketek and Study 3014 in the months to come.



Read more from this blogger

ADVERTISEMENTS

ADVERTISE HERE

30lbs in 3 Weeks- No Diet

Amazing Weight Loss Secret. As Seen on Oprah and 60 Minutes.
www.Lipocerin.com

Millions have Quit!

Try Cigarrest's smoking cessation program FREE! Proven to work!
www.cigarrest.com

Senator Grassley's December 2007 Letter To FDA Questions Agency's Approval Of Ketek

Sanofi-Aventis Antibiotic Has Been Subject Of Controversy Since Reports of Liver Damage Surfaced In Early 2006 (Posted by...



AIDS Orphans Rising: What You Should Know and What You Can Do To Help Them Succeed

There are alarming statistics that warn "every 14 seconds a Child Headed Household is formed." Sister Mary...



Restless Leg Syndrome Doubles Risk of Cardiovascular Disease

Increased cardiovascular disease, when talked about in reference to restless leg syndrome.

U.S. • WORLD • POLITICS • HEALTH • SCITECH • EN

Health Section

Top News Story



Re-booting Your Vision

AP WIRES

- Jolt Delayed in Third of Cardiac Arrests
- Fewer NY High School Students Smoke
- Sleep Disruptions May Up Diabetes Risk
- Whites More Likely to Get ER Narcotics
- Pa. Study to Probe Vitamin C, Cancer
- Researchers Work on Cocaine Vaccine
- Doctors Target Germs' Ability to Cluster
- UVa. Tests Viagra-Like Drug for Women
- CDC Seeks 44 on Flight With TB Patient
- Copper, Silver Tested As Germ Wards

[News Archive](#)

MARKETPLACE

- JOBS
- AUTOS
- MORTGAGES
- PERSONALS
- RELATIONSHIPS

monster' JOB SEARCH

Enter Keywords

Enter City

State

 Find a Car	 Find a Job
 Find a Date	 Find a Mortgage
 Get Voicemail	 Find Love

 Free Credit Score	 Fox News Shop	 Free Shipping!	
-----------------------	-------------------	--------------------	--

SEARCH

News Alerts RSS Feeds

Podcasts Make FOXNEWS.COM Your Home Page

Home | [U.S.](#) | [World](#) | [Politics](#) | [FOX News Polls](#) | [Business](#) | [Health](#) | [SciTech](#) | [Entertainment](#) | [Video](#) | [Opinion](#) | [MyNews](#) | [Sports](#) | [Weather](#)

[Radio](#) | [Mobile](#) | [FOX & Friends](#) | [Studio B](#) | [Your World](#) | [Big Story](#) | [Special Report](#) | [FOX Report](#) | [O'Reilly Factor](#) | [Hannity & Colmes](#) | [On the Record](#) | [RedEye](#) | [FNC iMag](#) | [uReport/ uAsk](#) | [FOX Fan](#) | [News Archive](#) | [FOX Around The World](#) | [FOX Sports](#) | [Contact US](#) | [Upgrade Central](#) |

[FAQs](#)

[Advertise on Fox News Channel, FOXNews.com and FOX News Radio.](#) [Advertising Specifications \(PDF\).](#) [Jobs at FOX News Channel.](#) [Internships At Fox News](#)
[Terms of use.](#) [Privacy Statement.](#) For FOXNews.com comments write to foxnewsonline@foxnews.com; For FOX News Channel comments write to
yourcomments@foxnews.com

This material may not be published, broadcast, rewritten, or redistributed. © 2007 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.